Method for preparing a vaccine from Streptococcus mutans for dental caries and vaccinal compositions for dental caries used as nasal drops

Abstract: A method for preparing a vaccine for dental caries comprises the step of culturing a variant which is obtained by integrating a protein antigen (PAc)-expressing gene into the chromosomal gene of a Streptococcus mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of oral Streptococcus mutans or it being extracellularly produced by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. Streptococcus mutans GS-5 (K-3), in which a protein antigen-­ expressing gene is integrated into the chromosomal gene thereof, has an ability of producing the protein antigen on the surface of the cells or extracellularly. A preventive vaccine composition for dental caries for nasal drops comprises the protein antigen thus produced by the strain: Streptcoccus mutans , the vaccine being intranasally administered. The method makes it possible to enhance the yield of PAc and to simplify processes for purifying PAc. The vaccine composition makes it possible to internally easily absorb the protein antigen, PAc, in high efficiency and it also makes it possible to effectively increase the antibody titer observed after the administration thereof.

Description: The present invention relates to a method for preparing a vaccine for dental caries, a novel variant of Streptococcus mutans GS-5 as well as a vaccine composition for dental caries which is used as nasal drops. The Streptococcus mutans group is the most crucial pathogenic factor in dental caries in human beings and animals. The S. mutans group is divided into 7 species depending on the characteristics of their DNA's and S. mutans of serotype, c , which is most closely related to human dental caries, posesses, on its surface, substances having various antigenicities such as serotype-specific polysaccharide antigens, lipoteichoic acid and protein antigens. One of these substances present on the bacterial cell surface, a protein antigen having a molecular weight of about 190,000 determined by SDS polyacrylamide gel electrophoresis, is a fine fibrous structure called fimbriae. This protein antigen is known variously as I/II, B, P1 and IF and it does not yet have a uniform name. Thus, this protein antigen is herein called PAc (protein antigen serotype c ). The cloning of the PAc gene of Streptococcus mutans MT 8148 (serotype c) and its expression is disclosed in Mol. Microbiol. 3(2) (1989), 221-228 and in Mol. Microbiol. 3(5) (1989), 673-678, respectively. The protein antigen of S. mutans has thus come to attract much interest in connection with development of a vaccine for dental caries. For instance, JP-A-56-501364 proposes the use of the antigen I/II possessing specific properties as a vaccine for dental caries and JP-A-58-164518 discloses a vaccine for preventing the decay of teeth. The vaccine comprises, as an antigen, the component of bacterial cells of microorganisms belonging to genus Streptococcus or an extract thereof. However, even if S. mutans is cultured in 10 liters of a culture medium and PAc is extracted therefrom, only several mg of PAc can be recovered. Thus, this technique cannot be put to practical use. In addition, the purification process for removing impurities from the resulting culture medium requires a great deal of labor and time since the concentration of PAc in the culture medium is very low. Under such circumstances, the inventors of this invention have tried to insert a PAc-expressing gene ( pac gene) of S. mutans into a host such as E. coli ( Escherichia coli ) or S. milleri (a species of Streptococcus ) to thus make the host cells produce rPAc. However, no increase in yield was achieved because the gene was integrated into the bacteria of different species and rPAc was not externally secreted. In this respect, the term "rPAc" herein means PAc obtained through gene recombination (recombinant PAc) and it is a protein having a structure substantially identical with that of PAc. Moreover, the inventors linked the pac gene to a plasmid-shuttle vector which can proliferate in both E. coli sand Streptococcus host cells and inserted it into a S. mutans GS-5 strain which cannot express PAc. The results are reported in Review of Nippon Dentistry Society, 1989, No. 555. However, this method suffers from various problems. For instance, after insertion of the pac gene into the cells of the GS-5 strain, it is sometimes observed that the plasmid carrying the gene is left out of the resulting recombinant bacterial cells and thus the variant stops the production of PAc and the products are insufficient in their uniformity. On the other hand, there have been known a protective vaccine for dental caries which contains the foregoing protein antigen, i.e., PAc and the vaccine has been used through injection or oral administration. However, if immunization is carried out by injection via skin, muscle or veins, local inflammation or even functional disorders may possibly be caused. In addition, since the injection is accompanied by pain, it is difficult to immunize an infant or a child through injection and patients are in general reluctant to have a vaccine injected at certain portions such as, for instance, near the parotid. Furthermore, it is difficult to increase the antibody titer in saliva by the administration through injection. Moreover, if it is orally administered, it may be digested in the stomach. Also, oral administration is liable to cause immune tolerance and consequent loss of response to the corresponding antigen. Besides, a high antibody titer cannot be achieved by the oral immunization. An object of the present invention is to provide a method for preparing a vaccine for dental caries which makes it possible to enhance the yield of PAc and to simplify processes for purifying PAc as well as a variant of S. mutans GS-5 in which a pac gene is integrated into its chromosome. Another object of the present invention is to provide a vaccine composition whose component, the protein antigen PAc, is internally easily absorbed, in high efficiency, by a subject for immunization. A further object of the present invention is to provide a vaccine composition capable of effectively increasing the antibody titer in a subject for immunization after the administration thereof and capable of sufficiently showing its vaccination effect. The method for preparing a vaccine for dental caries comprises the step of culturing a variant of an S. mutans GS-5 strain in which a protein antigen (PAc)-expressing gene which is obtained by integrating a protein antigen (PAc)-expressing gene of Streptococcus mutans into the chromosome of a Streptococcus mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of Streptococcus mutans or it being secreted by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. In a preferred embodiment, the molecular weight is about 190,000. The novel strain ( Streptococcus mutans GS-5 (K-3) FERM BP-2437) of the present invention was established through genetic engineering. More specifically, it was established by integrating the pac gene into the chromosome of oral Streptococcus , i.e. Streptococcus mutans host cells, to transform the host cells to thus substantially improve their productivity of PAc. The preventive vaccine for dental caries of the present invention comprises the protein antigen (PAc) which is produced on the surface of the cells of oral Streptococcus mutans or extracellularly produced, i.e. secreted by the microorganism. The composition is used in the form of nasal drops, i.e. it is adapted for intranasal administration. The preventive vaccine for dental caries in the form of nasal drops may further comprise a surfactant, cholera toxin B subunit or a bile acid or a derivative thereof. Further embodiments of the present invention are characterised in the claims. Fig. 1 is a diagram for illustrating the result of agarose electrophoresis of a plasmid-containing faction; and Fig. 2 is a diagram for showing the results of the Southern blot analysis of a chromosomal DNA using a ³²P-labeled erythromycin-resistant gene, Bam HI fragment, as a probe. In the present invention, the S. mutans GS-5 strain is employed as host bacteria, while any donor bacteria may be used so far as they are strains belonging to species S. mutans capable of producing PAc and preferred are, for instance, strains of c serotype, e serotype and f serotype. Thus, optimum suppression of change in the structure of the rPAc produced can be realized by selecting host and donor bacteria from those belonging to the same species. The S. mutans GS-5 strain is a known strain of S. mutans which is incapable of producing PAc and is preserved at various research institutes such as universities. The applicant of this invention deposited it with the Fermentation Research Institute (FRI) under an accession number of FERM BP-2436 under a designation of Streptococcus mutans GS-5 strain so that a third party can easily obtain it. Examples of the donor bacteria used in the present invention include Streptcoccus mutans NCTC 10449, Streptococcus mutans MT8148, Streptococcus mutans Ingbritt, Streptococcus mutans MT6, Streptococcus mutans JC2, Streptococcus mutans MT118, Streptococcus mutans C67-1, Streptococcus mutans OMZ70, Streptococcus mutans MT6801, Streptococcus mutans JC 1-5, Streptococcus mutans ATCC 33477, Streptococcus mutans SE11, Streptococcus mutans OMZ175, Streptococcus mutans MT557, Streptococcus mutans P2 and Streptococcus mutans PK-1. With the use of such donor bacteria, a gene which encodes PAc is inserted into the chromosome of the Streptococcus mutans GS-5 strain in a manner conventionally known in the art and thus the Streptococcus mutans GS-5 (K-3) strain of the present invention can be obtained. In this process, as the vector (plasmid for transferring PAc), there may be used, for instance, shuttle vectors pSA3 and pVA981 and as restriction enzymes for cleavage, there may be used, for instance, Bam HI, Sph I, Bgl II, Eco RI, Eco T14I, Hin d III, Pst I and Sac I. In the present invention, examples of the genes which encode the protein antigen (PAc) having a molecular weight ranging from about 170,000 to 220,000 preferably 180,000 to 210,000, include base sequences which encode the fragment substantially comprising 1,565 amino acid residues from the initiation codon (ATG) to the termination codon (TGA) of the following base sequence and fragments thereof. In addition, it is also possible to use base sequences in which a part thereof is replaced with other bases or one or more of the bases are deleted and which exhibit antigenicity substantially identical with that of PAc. Since the strain GS-5 (K-3) of the present invention is obtained by integrating the pac gene into the chromosomal DNA of the strain GS-5, the leaving out of the pac gene from the strain is hardly caused and the strain extracellularly produces rPAc in high yield. The site of the chromosomal DNA of the strain on which the pac gene exists can be confirmed by the Southern blot technique or the like. Therefore, rPAc can be obtained in high efficiency by isolating such a strain and culturing the same. Moreover, the processes for purifying rPAc can be substantially simplified since the content of rPAc in the culture supernatant is very high. The resulting rPAc can be used as a vaccine for dental caries in a variety of forms. The strain GS-5 (K-3) of the present invention can be cultured, for instance, in the following manner. 37 g of a brain heart infusion medium is dissolved in 1 ℓ of distilled water, then the resulting solution is sterilized at 121 ° C for 20 minutes and 1 mℓ of a 5 mg/mℓ erythromycin solution which has been filtered and sterilized in advance is added to and mixed with the foregoing solution to give a culture medium. The culture medium is dispensed in 10 mℓ portions into 24 mℓ sterilized test tubes, the strain GS-5 (K-3) is inoculated into each test tube and cultured at 37° C for 18 hours to thus give a seed cultue liquid. 100 mℓ of the seed culture liquid is added to a 2 ℓ volume flask in which 1 ℓ of a culture medium having the same composition has been added and cultured at 37° C for 18 hours to thus give a culture medium containing microorganisms. The medium is centrifuged at 10,000 X g for 15 minutes to obtain a culture supernatant. The purification of rPAc from the culture supernatant can be performed by various means. For instance, there can be used gel filtration methods such as those in which dextrans or agaroses are employed as a stationary phase; ion-exchange techniques such as those in which AE, DEAE, QAE, CM, SP, Phospho or the like is used as an ion-exchange resin; hydrophobic chromatography techniques such as those in which Octyl Sepharose, Phenyl Sepharose or the like is employed as a stationary phase; and affinity chromatography techniques. The resultant vaccines for dental caries are administered, for instance, orally or via subcutaneous injection. The dose thereof desirably ranges from about 10 µg to about 50 mg and preferably 10 µg to 10 mg and the optimum dose thereof is 1 mg. The bacteriological properties of the Streptococcus mutans GS-5 (K-3) (FERM BP-2437) are as follows. The determination of these bacteriological properties and the classification are performed according to the methods disclosed in Bergey's Manual of Systematic Bacteriology, 1986, 2 . A. Morphological Features When the strain was cultured in a brain-heart infusion medium at 37 ° C for 2 days, the following morphological features were observed: 1) Shape and Size of the Cell It is a coccus; the size thereof ranges from 0.5 to 0.75µ m and it forms linkages. 2) Polymorphism: none. 3) Motility: none. 4) Spore: none. 5) Gram Staining: positive. 6) Resistance to Acid: negative. B. Culturing Properties (Cultivability) 1) Brain heart infusion agar plate culture: The strain grows at pH ranging from 7.0 to 7.4 and forms circular, flat, entire colonies. The surface of these colonies is smooth and glossy and the color thereof is yellowish white or pale brown. 2) Brain heart infusion agar slant culture: It grows at pH ranging from 7.0 to 7.4 on wide belt-shaped regions and forms glossy yellowish white or pale brown colored colonies. 3) Brain heart infusion liquid culture: It grows at pH ranging from 7.0 to 7.4, but does not form pellicles and the turbidity of the culture medium is uniform. 4) Broth gelatin stab culture: The culture medium is not liquefied at all. 5) Litmus· milk: It grows sufficiently, produces acids and causes coagulation of milk. C. Physiological Properties 1) Reduction of nitrates: negative. 2) Denitrification reaction: negative. 3) MP test: positive. 4) VP test: positive. 5) Production of indole: negative. 6) Formation of hydrogen sulfide: negative. 7) Hydrolysis of starches: negative. 8) Use of citric acid: It does not use citric acid in either Koser's or Christensen's mediums. 9) Use of inorganic nitrogen: It does not use either nitrates or ammonium salts. 10) Generation of dyes: negative. 11) Urease: negative. 12) Oxidase: negative. 13) Catalase: negative. 14) Range of growth conditions: The growth temperature ranges from 33 to 38 ° C (optimum temperature: 37° C). The growth pH thereof ranges from 6.0 to 7. 4. 15) Behavior against oxygen: facultative anaerobic. 16) O-F test: positive. 17) Generation of acids and gases from sugars: It produces acids from D-glucose, D-mannose, D-fructose, D-galactose, malt sugar (maltose), cane sugar (sucrose), trehalose, D-sorbit and D-mannit, but does not generate gases at all. It generates neither acids nor gases from L-arabinose, D-xylose, inosit, glycerin and starches. D. Other Miscellaneous Characteristics 1) Decomposition of arginine: negative. 2) Hemolysis type: γ hemolysis. 3) Resistance to sodium chloride: resistant to 4% sodium chloride solution. 4) Other properties found necessary: It hydrolyzes esculin and is resistant to 2 U/mℓ of bacitracin. It generates acids from inulin, D-raffinose and D-melibiose. It synthesizes glucan from sucrose. The aforesaid properties can be summarized as follows: the strain is a gram positive Streptococcus which produces acids from inulin, D-raffinose, D-melibiose and D-sorbit, which does not hydrolyze arginine and which is resistant to bacitracin. Thus, it can be concluded that the microorganism is a strain belonging to species Streptococcus mutans . In the vaccine of the present invention, it is also possible to use the cortex of the cells of the foregoing S. mutans or those which are extracellularly produced by the strain in addition to the protein antigen (PAc) obtained by the method described above. More specifically, PAc is a protein present on the cortex of the cell bodies, but the strain secretes PAc extracellularly. Therefore, the easiest way for the preparation of the vaccine is to use the culture medium obtained after the cultivation of S. mutans . For instance, S. mutans strain ATCC 25175 is cultured in an outer solution obtained by dialyzing a brain-heart infusion culture medium (available from BBL Company, Difco Company etc.), the resulting culture supernatant is subjected to a salting out process carried out at a saturated ammonium sulfate concentrtion (60%), the product salted out is dissolved in a 50 mM Tris-hydrochloric acid buffer and then dialyzed against the same buffer. Subsequently, the preparation thus obtained is added to a column packed with DEAE Sephacel® (available from Pharmacia Co., Ltd.) which has been equilibrated with the same buffer and elution is performed by a linear concentration gradient of NaCl ranging from 0 to 0.5 M whereby PAc is eluted at an NaCl concentration of about 0.2 M. The resulting PAc-containing fractions are pooled, concentrated and subjected to gel filtration using Sepharose CL-6B® to obtain purified PAc-containing fractions which are used as the purified PAc. Further, proteins equivalent to PAc and rPAc obtained from strains belonging to species Streptococcus mutans other than the S. mutans serotype c , which produce protein antigens common to PAc are also included in the scope of this invention and hence may be used in the vaccine composition of the present invention. In the present invention, to the purified PAc there may optionaly be added carriers, diluents, or other additives such as preservatives, humectants, binders, adjuvants and agents for accelerating absorption to obtain pharmaceutical preparations used as nasal drops. The amount of PAc to be added to the vaccine composition suitably ranges from 0.05 to 50 mg/0.2mℓ and preferably 0.5 to 20 mg/0.2 mℓ. The vaccine composition of the present invention is preferably administered in an amount ranging from 0.05 to 0.6 m ℓ/dose. Moreover, the vaccine composition of the present invention is suitably administered 2 or more times and preferably 2 to 6 times to achieve the desired immunization effect. The vaccine composition of the present invention makes it possible to intranasally immunize a subject. Therefore, it may be easily administered even to many persons and the administration thereof is not accompanied by pain. Since at least two administrations are in general required for achieving the desired immunization effect, simplicity and the possibility of administration without pain are very important for the immunization procedures. The antibody titer of the vaccine composition of the present invention can effectively be increased by the addition of cholera toxin B, a surfactant or a bile acid or a derivative thereof to the composition for nasal drops. The amount of the cholera toxin B to be added to the composition suitably ranges from 10 µg to 20 mg/0.2 mℓ and preferably 50 µg to 10 mg/0.2 mℓ of the vaccine composition. The surfactants may be anionic surfactants, cationic surfactants, nonionic surfactants and/or amphoteric surfactants, in particular cationic surfactants are preferred. These surfactants may be used alone or in any combination. The amount of the surfactants to be incorporated into the vaccine composition suitably ranges from 0.01 to 10% by weight, preferably 0.1 to 5% by weight on the basis of the total eight of the composition for anionic and nonionic surfactants and suitably ranges from 0.001 to 1.0% by weight and preferably 0.01 to 0.5% by weight on the basis of the total weight of the composition for cationic surfactants. Examples of the anionic surfactants are carboxylic acid salts such as higher fatty acid salts (soaps) and N-acylamino acid salts of, for instance, lauroyl sarcosinate; sulfuric acid ester salts such as alkyl sulfates (for instance, lauryl sulfate), alkyl ether sulfates (for instance, polyoxyethylene alkyl ether sulfates) and fatty acid monoglyceride sulfates; alkane sulfonate; sulfosuccinates such as sodium dioctyl sulfosuccinate; N-acylsulfonates, fatty acid monoglyceride sulfonates and α-sulfofatty acid ester salts; alkyl phosphoric acid salts; and alkyl ether phosphoric acid salts. Examples of the cationic surfactants are quaternary ammonium salts such as benzethonium chloride, benzalkonium chloride, cetyl pyridinium chloride, chlorohexyzine· gluconate and chlorohexyzine· hydrochloride. Examples of the nonionic surfactants are polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers (such as Triton X-100), polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters (such as Tween 20® and Tween 80®), polyoxyethylene (hardened) castor oil, polyoxyethylene glycerin fatty acid esters and polyoxyethylene-polyoxypropylene copolymers. Among the surfactants listed above, preferred are nonionic surfactants such as polyoxyethylene octyl ether, polyoxyethylene nonyl ether, polyoxyethylene lauryl ether, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, polyoxyethylene octylphenyl ether and Triton X100®, whose average molar number of added ethylene oxide ranges from 5 to 30; cationic surfactants such as benzethonium chloride and benzalkonium chloride; and anionic surfactants such as sodium lauryl sulfate and potassium lauryl sulfate. Examples of bile acids usable in the present invention include etiobilianic acid, etioallobilianic acid, etianic acid, 3-hydroxy-nor-5α-cholanic acid, dehydrocholic acid, cilianic acid, 12-ketocholanic acid, lithocholic acid, deoxycholic acid, chenodeoxycholic acid, cholic acid and cholanic acid. In addition to these compounds, it is also possible to use derivatives and salts such as sodium and potassium salts thereof and sodium and potassium salts of the derivatives. Among these derivatives of bile acids, preferred are amide compounds of bile acids with amino acids or aminosulfonic acids and their sodium and potassium salts are also suitably employed in the present invention. Examples of such amino acids and aminosulfonic acids are glycine, serine, asparagine, aspartic acid and taurine. Among these, particularly preferred are sodium taurocholate, sodium glycocholate, sodium cholate and sodium deoxycholate. The amount of these bile acids or the derivatives thereof to be incorporated into the vaccine composition of the present invention desirably ranges from 0.05 to 50 mg/0.2 mℓ and preferably 0.5 to 20 mg/0.2 mℓ. The protective vaccine composition for dental caries of the present invention may further comprise an adjuvant such as alum, aluminum hydroxide, aluminum phosphate, aluminum sulfate and muramyl dipeptide; adjuvant fat-soluble components (agents for accelerating absorption) such as oleic acid, stearic acid and palmitic acid; humectants such as glycerin, sorbite, xylite, mannite, lactite, maltite and polyethylene glycols (such as PEG 400 and PEG 4,000); preservatives such as sorbic acid, chlorobutanol, benzoic acid, o-oxybenzoic acid ester, boric acid, dehydroacetic acid and thymol; and binders such as sodium polyacrylate, polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxy methyl cellulose, methyl cellulose, hydroxyethyl cellulose, carrageenan, sodium alginate, gum arabic, xanthane gum, montmorillonite, kaolin, hydrated silica, aluminum magnesium silicate and hectorite. Alternatively, mammalian or birds are immunized with the protein antigen PAc of the present invention per se or a combination thereof with a surfactant and/or CTB to obtain antibodies and the resulting antibodies may be used in the protective vaccine composition for dental caries of the present invention as effective components. According to the protective vaccine composition for dental caries, the antibody titer can effectively and simply be increased without pain by intranasally administering the protein antigen PAc. In addition, the antibody titer of the vaccine composition of the present invention can more efficiently be increased if the protein antigen PAc is administered together with a surfactant, cholera toxin B or a bile acid or a derivative thereof. Therefore, the present invention further includes two aspects, the one being a method for intranasally administering a vaccine composition for dental carries which comprises a protein antigen PAc and a carrier or a diluent and optionally a surfactant, cholera toxin B or a bile acid or a derivative thereof and the other being use of protein antigen PAc for the preparation of the vaccine composition for dental carries as nasal drops. The present invention will hereunder be explained in more detail with reference to the following non-limitative Examples. Example 1 (1) Integration of the pac Gene into the Strain GS-5 The plasmid pPC77 carrying the pac gene of Streptcoccus mutans NCTC 10449 and a shuttle vector pSA3 were cleaved with restriction enzymes Bam HI and Sph I respectively. The cleaved pPC77 and pSA3 were linked with a T4 DNA ligase, the resultant plasmid was inserted into host cells, E . coli strain HB 101 (deposited with National Institute for Genetics under the accession number of ME 8568) by a transformation technique and a clone which was resistant to chloramphenicol and sensitive to ampicillin and tetracycline was selected. Recombinant plasmids were extracted from clones whose capacity of producing PAc had been confirmed by a colony immune blot technique or Western blot technique, the size thereof was determined by agarose electrophoresis and it was thus found that all the clones had the recombinant plasmid of 16.4 kb. One of these plasmids was named K and the plasmid K was inserted into a strain, S. mutans GS-5, incapable of producing PAc by an electroporation technique to transform the strain. The resulting PAc-producing strain was named GS-5 (K-X). In the foregoing operations, a plurality of strains, GS-5 (K-X) were obtained, but their PAc-producing abilities differed from each other. Among these strains, the strains, GS-5 (K-3) having excellent PAc-prducing ability and GS-5 (K-9) which produced PAc, but whose PAc-producing ability was inferior to that of the former were examined on the sites at which the pac gene was inserted. (2) Determination of the Site at Which pac Gene Was Integrated The strains GS-5 and GS-5 (K-3) were lysed with lysozyme and the plasmids were separated from the chromosomal DNA's. The resulting fractions containing plasmid were analyzed by agarose electrophoresis and it was found that any plasmids were not present in the fractions thus obtained from the strains GS-5 and GS-5 (K-3) as shown in Fig. 1. On the other hand, the same procedures were repeated using the strain GS-5 (K-9) and it was found that the intended plasmid was present in the fraction thus obtained from the strain GS-5 (K-9). The chromosomal DNA was cleaved with Eco RI and then the resultant products were analyzed by the conventional Southern blot technique. When Bam HI fragments of the gene resistant to erythromycin were used as a probe, the chromosomal DNA's of the strains GS-5 and GS-5 (K-9) did not show any reactivity, while the fragment of about 16 kb of the chromosomal DNA of the strains GS-5 (K-3) exhibited reactivity therewith. The foregoing results clearly show that, in the strain GS-5 (K-3), the plasmid pSM1 was integrated into the chromosomal DNA of the strain GS-5 as a result of homologous recombination. On the other hand, in the strain GS-5 (K-9) which can produce PAc, but whose PAc-producing ability is inferior to that of the strain GS-5 (K-3), it is found that the pac gene was present in the plasmid, but not in the chromosomal DNA thereof. The Southern blot analysis is detailed in the article of E. M. Southern (1975) entitled "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", J. Mol. Biol., 98 , pp. 503-517. (3) Cultivation and Purification of rPAc (Recombinant PAc) The S. mutans strain GS-5 (K-3) was cultured in an external solution obtained by dialyzing TTY broth or BHI broth, the resulting culture supernatant was salted out at a saturated concentration of ammonium sulfate (60%), the products salted out were dissolved in 50 mM Tris-HCℓ buffer, dialyzed against the same buffer and the resulting dialyzate (preparation) was passed through a DEAE-cellulose column which had been equilibrated with the same buffer in advance. After passing the bed volume of the same buffer through the column two times, elution was performed at a linear concentration gradient of NaC ℓ ranging from 0 to 0.5 mole. As a result, PAc was eluted at an NaCℓ concentration of about 0.2 mole. This eluted fraction as such can be used as a purified preparation of rPAc. When the strain GS-5 (K-3) is used, the purification processes can be substantially simplified as described above since the content of rPAc in the culture supernatant is very high. The rPAc thus prepared can be used as vaccines for dental caries in various forms. In the same manner used above, an NCTC 10449 strain, a GS-5 strain and a GS-5 (K-9) strain were likewise cultured, PAc secreted in the culture supernatants was purified, and the amount thereof (expressed in the reduced amount of the proteins contained) was determined by the Lowry method. The results are listed in the following Table I as relative values. As seen from these results, the GS-5 (K-3) strain of the present invention produces PAc in high yield. Strain Used Relative Amount of PAc Produced Streptococcus mutans NCTC 10449 1 Streptococcus mutans GS-5 0 Streptococcus mutans GS-5 (K-3) 48 Streptococcus mutans GS-5 (K-9) 12 (4) Immunization Test with rPAc Compositions listed in the following Table II were dissolved in phosphate-buffered saline (PBS) and 0.1 mℓ each of the resulting solution was intraperitoneally injected twice in groups of mice (5 mice per group) at 10-days intervals to thus immunize the mice. 7 days after the second immunization, blood was sampled from the mice and the antibody titer against rPAc in blood was determined by the enzyme-linked immuno sorbent assay (ELISA method). The results obtained are summarized in Table II. In Table II, the antibody titer is expressed in the reciprocal of the highest rate of dilution at which the resulting serum showed reactivity in the ELISA method. In this respect, the serum was first diluted 10 times and thereafter it was diluted two times in order to determine the highest rate of dilution. Group No. Amount of rPAc (in 1 mℓ) Antibody Titer in Blood 1 none (only PBS) < 10 2 100 µg 980 Example 2 Groups of 5-week-old BALB/c mice (each comprising 5 animals) were immunized by intranasally administering 10 µℓ each of a solution containing PAc alone or a mixed solution containing PAc as well as a surfactant, cholera toxin B or a bile acid (salt) (the composition thereof is given below), three times at one-week intervals and further 4 weeks after the third immunization a fourth immunization was likewise performed. Then blood was sampled from each mouse and the antibody titer in blood was determined by the ELISA method. The results obtained are listed in the following Table III. In Table III, the antibody titer is expressed in the titer of the serum diluted 100 times, which was obtained 7 weeks after the final intranasal immunization. Composition of the Mixed Solution (unit dose :10 µℓ) Component Amount PAc (rPAc) 1 mg/mℓ Cholera toxin B 0.5 mg/mℓ Anionic surfactant 0.2% by weight Cationic surfactant 0.2% by weight Nonionic surfactant 0.2% by weight Bile acid (salt) 0.2% by weight Composition of the solution administered ELISA OD₄₀ ₅ PAc + cholera toxin B 0.55 PAc + benzethonium chloride 0.52 PAc + SDS 1 0.42 PAc + Triton X-100® 2 0.25 PAc + glycolic acid 0.50 PAc + sodium glycolate 0.52 PAc alone 0.12 Example 3 The following exemplary preparations 1 to 13 of the protective vaccine composition for dental caries according to the present invention were prepared. Preparation 1 Benzethonium chloride 0.1 g Glycerin 0.8 g Hydroxyethyl cellulose 0.8 g PAc 0.25 g Purified water balance total 100 g Preparation 2 Sodium lauryl sulfate 0.4 g Xylite 0.5 g Hydroxymethyl cellulose 0.8 g PAc 0.25 g Benzoic acid 0.1 g Purified water balance total 100 g Preparation 3 Sucrose monopalmitic acid ester 1.2 g sorbite 0.6 g Methyl cellulose 0.6 g PAc 0.4 g Purified water balance total 100 g Preparation 4 Glycerin 0.8 g Hydroxyethyl cellulose 0.5 g rPAc 0.25 g Cholera toxin B 0.08 g Butyl Paraben HC1 0.1 g Purified water balance total 100 g Preparation 5 Benzethonium chloride 0.1 g Polyoxyethylene hardened castor oil 0.8 g Xylite 0.5 g Hydroxymethyl cellulose 0.8 g rPAc 0.5 g Benzoic acid 0.1 g Alum 0.02 g Purified water balance total 100 g Preparation 6 Cetyl pyridinium chloride 1.5 g Sorbite 0.7 g Gum arabic 0.3 g rPAc 0.5 g Muramyl dipeptide 0.05 g Purified water balance total 100 g Preparation 7 Glycerin monolauric acid ester 0.4 g Polyoxyethylene sorbitan fatty acid ester 0.5 g Glycerin 0.8 g Hydroxymethyl cellulose 0.5 g PAc 0.25 g Cholera toxin B 0.08 g Purified water balance total 100 g Preparation 8 Glycerin 0.8 g Hydroxyethyl cellulose 0.5 g PAc 0.8 g Butyl Paraben HC1 0.1 g Stearic acid 0.05 g Purified water balance total 100 g Preparation 9 Polyoxyethylene sorbitan stearic acid ester 0.5 g Glycerin 0.8 g Hydroxyethyl cellulose 0.5 g PAc 0.5 g Cholera toxin B 0.08 g Lauryl di(aminoethyl)glycine hydrochloride 0.2 g Purified water balance total 100 g Preparation 10 Chlorohexyzine gluconate 0.1 g Sodium polyacrylate 0.2 g rPAc 0.25 g Aluminum hydroxide 0.1 g Oleic acid 0.5 g Triton 100® 0.8 g Purified water balance total 100 g Preparation 11 Glycerin 0.8 g PAc 0.08 g Butyl Paraben hydrochloride 0.1 g Sodium glycocholate 0.1g Stearic acid 0.05 g Alum 0.1 g Purified water balance total 100 g Preparation 12 Sorbite 2.0 g rPAc 0.05 g Butyl Paraben hydrochloride 0.1 g Cholic acid 0.2 g Polyoxyethylene sorbitan fatty acid ether 1.0 g Purified water balance total 100 g Preparation 13 Glycerin 2.0 g rPAc 0.08 g Sodium glycocholate 0.1 g Cholera toxin B 0.04 g Purified water balance total 100 g

Claims: A method for preparing a vaccine for dental caries comprising a protein antigen of Streptococcus mutans , said method comprising the step of culturing a variant which is obtained by integrating a protein antigen-expressing gene of Streptococcus mutans into the chromosome of a Streptococcus mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of Streptococcus mutans or it being secreted by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. The method of claim 1 wherein the protein antigen has a molecular weight of about 190,000. The method of claim 1 or 2 wherein the Streptococcus mutans GS-5 strain is FERM BP-2436. The method of claim 1 wherein said variant that is obtained is Streptococcus mutans GS-5 (K-3) FERM BP-2437. Streptococcus mutans GS-5 (K-3) FERM BP-2437 in which a protein antigen-expressing gene of Streptococcus mutans is integrated into the chromosome thereof and which has an ability of producing the protein antigen, the protein antigen being produced on the surface of cells of Streptococcus mutans , or it being secreted by the microorganism. Streptococcus mutans GS-5 (K-3) FERM BP-2437. A vaccine composition for dental caries comprising a protein antigen of Streptococcus mutans which is produced on the surface of cells of Streptococcus mutans or secreted by the microorganism, the vaccine being characterised by being adapted for intranasal administration. The vaccine according to claim 7 comprising Streptococcus mutans GS-5 (K-3) FERM BP-2437. The vaccine according to claim 7 or 8 which is in the form of nasal drops. The vaccine according to any one of claims 7 to 9 further comprising a surfactant. The vaccine according to any one of claims 7 to 10 further comprising cholera toxin B. The vaccine according to any one of claims 7 to 11 further comprising a bile acid or a derivative thereof.

Inventors: KOGA TOSHIHIKO, OHTA HIROTAKA, OKAHASHI NOBUO, SHIBUYA KOJI, TAKAHASHI ICHIRO, KOGA, TOSHIHIKO, OHTA, HIROTAKA, OKAHASHI, NOBUO, SHIBUYA, KOJI, TAKAHASHI, ICHIRO
Applicants: LION CORP, NAT INST HEALTH, LION CORPORATION, THE NATIONAL INSTITUTE OF HEALTH
Application year: 1990
Main classification: A61K39
IPC codes: A61K39, C07K14, A61K9